Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Treatment outcome of all seven patients

From: Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma

Number 1stassessment after cycles 1-4 2ndassessment after cycles 5-8 Bevacizumab maintaining times Radiotherapy (Gy) 3rdassessment
1 CRu CR 0 40.6 CR
2 CRu CR 7 40 CR
3 CRu CR 7 36 CR
4 PD NAa 0 No NA
5 CRu CR 6 42 CR
6 CRu CR 4 42 CR
7 PR CRu 0 50 CR
  1. CR: complete remission, CRu: complete remission unconfirmed, PR: partial remission, PD: progressive disease. NA, not assessed. aPatient No. 4 withdrew after the first assessment.